Immunicum's Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology

Gothenburg, Sweden, 2015-03-13 09:06 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the Company's Chief Scientific Officer, Dr. Alex Karlsson-Parra, has presented the technology behind the cancer vaccine INTUVAX at the conference "Symposium on Breakthroughs in Clinical & Translational Immunology", held on March 12, 2015, at Karolinska Institutet in conjunction with other world-leading researchers in the field of immunology.

The symposium was on advances in clinical and translational immunology, brought by the Department of Cell and Molecular Biology at Karolinska Institutet. The symposium covered fields including organ and composite tissue transplantation, cell transplantation, cancer immunotherapy, immune tolerance and mesenchymal stromal cell therapy.

Immunicum's Chief Scientific Officer, Dr. Alex Karlsson-Parra, presented the Company's technology and clinical data on the topic of cancer immunotherapy, in conjunction with a talk by the world-leading researcher in adoptive immunotherapy, Dr. Steven A. Rosenberg from the National Cancer Institute. Updated survival data from Immunicum's formally completed phase I/II-study in 12 patients with metastatic renal cell carcinoma, treated with the cancer vaccine INTUVAX, were announced. Seven of the 11 evaluable patients for efficacy are still alive. According to MSKCC-criteria, the median overall survival for the entire patient population is currently over 23 months compared to expected 15.2 months for patients receiving standard treatment with the drug sunitinib. For the group of patients with poor prognosis, median overall survival is currently at over 22 months compared to expected 9 months for patients treated with sunitinib. Patients with intermediate prognosis exhibit an ongoing median overall survival of 27 months compared to expected 26 months for patients treated with sunitinib. The final median overall survival has not yet been reached for any patient group.

 

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Tel: +4631-41 50 52,

jamal.el-mosleh@immunicum.com

 

Certified Adviser Redeye AB

Tel: 08-545013 31. www.redeye.se

 

About Immunicum

Immunicum AB (publ) develops therapeutic cancer vaccines. A phase II study of the Company's most advanced project - INTUVAX® against renal cancer - has been approved by the Swedish Medical Products Agency and is expected to start in spring 2015. The project portfolio contains three additional projects against various tumors, including an ongoing clinical study in patients with liver cancer.

www.immunicum.com